Trial Profile

A Phase I/II, Open Label, Multicentre, Ascending Single Dose, Safety Study of a Novel Adeno- Associated Viral Vector (FLT180a) in Patients With Haemophilia B

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Verbrinacogene setparvovec (Primary)
Indications Haemophilia B
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms B-AMAZE; FIX-GT

Most Recent Events

17 Jun 2024 According to Freeline Therapeutics media release, Freeline Therapeutics has changed its name to Spur Therapeutics.
21 Jul 2022 According to a Freeline Therapeutics media release, long-term follow-up data for up to 3.5 years from this study published in the New England Journal of Medicine (NEJM)
21 Jul 2022 Results presented in the Freeline Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com